Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| ABBOTT LABORATORIESABT · Entity 2314 | Director | September 30, 2026 | October 03, 2026 |
| ALIGN TECHNOLOGY INCALGN · Entity 3488 | Director | May 20, 2026 | May 22, 2026 |
| Adaptive Biotechnologies CorpADPT · Entity 1126 | Director | March 06, 2023 | March 09, 2023 |
| American Exceptionalism Acquisition Corp. AAEXA · Entity 5376 | Director | September 25, 2025 | December 30, 2025 |
| SomaLogic, Inc.SLGCW · Entity 95310 | Director | September 01, 2021 | September 04, 2021 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
ABBOTT LABORATORIES
Report date September 30, 2026 · Filed October 03, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Equivalent UnitsSEC Table II · derivative / convertible security | Direct | 551 |
Reported balance
After 2026-09-30 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-09-30 · Grant · Acquired 318 · Balance 551 F1: Director fees credited to a stock equivalent unit account under a grantor trust established by the director and paid, in cash, generally at age 65 or upon retirement from the board. The stock equivalent units earn the same return as if the fees were invested in Abbott stock. F2: Balance includes stock equivalent units acquired pursuant to a dividend reinvestment feature. |
Filing footnotes · ownership attribution and instrument terms
F1: Director fees credited to a stock equivalent unit account under a grantor trust established by the director and paid, in cash, generally at age 65 or upon retirement from the board. The stock equivalent units earn the same return as if the fees were invested in Abbott stock.
F2: Balance includes stock equivalent units acquired pursuant to a dividend reinvestment feature.
ALIGN TECHNOLOGY INC
Report date May 20, 2026 · Filed May 22, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 3,553 |
Reported balance
After 2026-05-20 transaction · row 1
1 source rowRow 1 · 2026-05-20 · Exercise / conversion · Acquired 1,745 · Balance 3,553 |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2026-05-20 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-05-20 · Exercise / conversion · Disposed 1,745 · Balance 0 F1: 100% of the restricted stock units ("RSUs") granted on May 21, 2025 vested on May 20, 2026 and shares were delivered to the Reporting Person. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 1,836 |
Reported balance
After 2026-05-20 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2026-05-20 · Grant · Acquired 1,836 · Balance 1,836 F2: 100% of the RSUs granted on May 20, 2026 will become vested on the earlier of (i) May 20, 2027 or (ii) the date of the next annual meeting of stockholders. Shares will be delivered to the Reporting Person on such vesting date assuming the continued service of the Reporting Person on such vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: 100% of the restricted stock units ("RSUs") granted on May 21, 2025 vested on May 20, 2026 and shares were delivered to the Reporting Person.
F2: 100% of the RSUs granted on May 20, 2026 will become vested on the earlier of (i) May 20, 2027 or (ii) the date of the next annual meeting of stockholders. Shares will be delivered to the Reporting Person on such vesting date assuming the continued service of the Reporting Person on such vesting date.
Adaptive Biotechnologies Corp
Report date March 06, 2023 · Filed March 09, 2023
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 22,968 |
Reported balance
After 2023-03-06 transaction · row 1
1 source rowRow 1 · 2023-03-06 · Grant · Acquired 14,775 · Balance 22,968 |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $8.46 · Expires 2033-03-06 | Direct | 23,329 |
Reported balance
After 2023-03-06 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2023-03-06 · Grant · Acquired 23,329 · Balance 23,329 F1: The option will vest in equal monthly installments over one year from March 4, 2023, subject to continued service as a director through such vesting dates. |
Filing footnotes · ownership attribution and instrument terms
F1: The option will vest in equal monthly installments over one year from March 4, 2023, subject to continued service as a director through such vesting dates.
American Exceptionalism Acquisition Corp. A
Report date September 25, 2025 · Filed December 30, 2025 · Amendment
Amendment: balances below belong to this corrected disclosure, not necessarily a complete replacement of earlier positions.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Class B Ordinary SharesSEC Table II · derivative / convertible security | Direct | Not disclosed |
Reported balance
Holding disclosure · report date 2025-09-25 · row 1
Amendment: may correct only part of an earlier disclosure.
1 source rowRow 1 · Balance Not disclosed F1: As described in the Issuer's Registration Statement on Form S-1, as amended (File No. 333-289701), under the heading "Description of Securities - Founder Shares," Class B ordinary shares will automatically convert into Class A ordinary shares on or prior to the tenth anniversary of the Issuer's initial business combination, upon the earlier of (A) the Issuer meeting certain share price performance thresholds following the completion of its initial business combination, and (B) subsequent to the completion of its initial business combination, the date on which a change of control occurs, in each case, on a one-for-one basis, subject to adjustment as provided therein. |
Filing footnotes · ownership attribution and instrument terms
F1: As described in the Issuer's Registration Statement on Form S-1, as amended (File No. 333-289701), under the heading "Description of Securities - Founder Shares," Class B ordinary shares will automatically convert into Class A ordinary shares on or prior to the tenth anniversary of the Issuer's initial business combination, upon the earlier of (A) the Issuer meeting certain share price performance thresholds following the completion of its initial business combination, and (B) subsequent to the completion of its initial business combination, the date on which a change of control occurs, in each case, on a one-for-one basis, subject to adjustment as provided therein.
SomaLogic, Inc.
Report date September 01, 2021 · Filed September 04, 2021
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Class A Common StockSEC Table I · non-derivative | Direct | 25,000 |
Reported balance
After 2021-09-01 transaction · row 1
1 source rowRow 1 · 2021-09-01 · Other · Acquired 25,000 · Balance 25,000 F1: In connection with the closing (the "Closing") of the business combination (the "Business Combination") between the Issuer (which was formerly known as CM Life Sciences II Inc. or "CMLS II") and SomaLogic, Inc. ("SomaLogic"), among other things, each share of CMLS II's Class B common stock converted pursuant to the terms of such stock into shares of the Issuer's Class A Common Stock on a one-for-one basis. |
| Warrants to purchase Class A Common Stock (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $11.50 · Expires 2026-09-01 | IndirectBy Conroy Family Foundation, Inc. | 166,666 |
Reported balance
After 2021-09-01 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2021-09-01 · Grant · Acquired 166,666 · Balance 166,666 F2: Following the completion of the Business Combination, warrants to purchase Class A Common Stock become exercisable on October 1, 2021, the date that is 30 days after the closing of the Business Combination. The Conroy Family Foundation, Inc. (the "Conroy Foundation") is the record holder of the Class A Common Stock exercisable upon the issuance of warrants reported herein. Mr. Conroy has voting and investment discretion with respect to the Class A Common Stock held of record by the Conroy Foundation. As such, Mr. Conroy may be deemed to have or share beneficial ownership of the securities held directly by the Conroy Foundation. Mr. Conroy disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein. |
| Class B Common StockSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2021-09-01 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2021-09-01 · Exercise / conversion · Disposed 25,000 · Balance 0 F1: In connection with the closing (the "Closing") of the business combination (the "Business Combination") between the Issuer (which was formerly known as CM Life Sciences II Inc. or "CMLS II") and SomaLogic, Inc. ("SomaLogic"), among other things, each share of CMLS II's Class B common stock converted pursuant to the terms of such stock into shares of the Issuer's Class A Common Stock on a one-for-one basis. |
Filing footnotes · ownership attribution and instrument terms
F1: In connection with the closing (the "Closing") of the business combination (the "Business Combination") between the Issuer (which was formerly known as CM Life Sciences II Inc. or "CMLS II") and SomaLogic, Inc. ("SomaLogic"), among other things, each share of CMLS II's Class B common stock converted pursuant to the terms of such stock into shares of the Issuer's Class A Common Stock on a one-for-one basis.
F2: Following the completion of the Business Combination, warrants to purchase Class A Common Stock become exercisable on October 1, 2021, the date that is 30 days after the closing of the Business Combination. The Conroy Family Foundation, Inc. (the "Conroy Foundation") is the record holder of the Class A Common Stock exercisable upon the issuance of warrants reported herein. Mr. Conroy has voting and investment discretion with respect to the Class A Common Stock held of record by the Conroy Foundation. As such, Mr. Conroy may be deemed to have or share beneficial ownership of the securities held directly by the Conroy Foundation. Mr. Conroy disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein.
Past disclosures · reporting ended (3)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
ARYA SCIENCES ACQUISITION CORP.
Report date July 01, 2020 · Filed July 07, 2020
Section 16 reporting ended · disclosed 2020-07-07. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Class B Ordinary SharesSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2020-07-01 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2020-07-01 · Disposition to issuer · Disposed 30,000 · Balance 0 F1: In connection with the merger of ARYA Sciences Acquisition Corp. (the "Issuer") with and into a subsidiary of Immatics N.V. ("IMTX"), and a series of related transactions (collectively, the "Business Combination"), the Class B Ordinary Shares, par value $0.0001 per share, of the Issuer held by the Reporting Person were exchanged for Ordinary Shares, nominal value EURO0.01 per share, of IMTX. Upon consummation of the Business Combination the Reporting Person is no longer subject to the reporting requirements of Section 16 with respect to the Issuer's securities. |
Filing footnotes · ownership attribution and instrument terms
F1: In connection with the merger of ARYA Sciences Acquisition Corp. (the "Issuer") with and into a subsidiary of Immatics N.V. ("IMTX"), and a series of related transactions (collectively, the "Business Combination"), the Class B Ordinary Shares, par value $0.0001 per share, of the Issuer held by the Reporting Person were exchanged for Ordinary Shares, nominal value EURO0.01 per share, of IMTX. Upon consummation of the Business Combination the Reporting Person is no longer subject to the reporting requirements of Section 16 with respect to the Issuer's securities.
EXACT SCIENCES CORP
Report date March 23, 2026 · Filed March 23, 2026
Section 16 reporting ended · disclosed 2026-03-23. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Ending reported balance
After 2026-03-23 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2026-03-23 · Grant · Acquired 119,312 · Balance 1,397,738 F1: On March 23, 2026, pursuant to the terms of that certain Agreement and Plan of Merger (the "Merger Agreement"), dated as of November 19, 2025, by and among Exact Sciences Corporation, a Delaware corporation (the "Issuer"), Abbott Laboratories, an Illinois corporation ("Parent"), and Badger Merger Sub I, Inc., a Delaware corporation and a direct, wholly owned subsidiary of Parent ("Merger Sub"), Merger Sub merged with and into the Issuer (the "Merger"), with the Issuer surviving the Merger as a direct, wholly owned subsidiary of Parent. F2: At the effective time of the Merger (the "Effective Time"), each performance based restricted stock unit ("PSU") outstanding as of immediately prior to the Effective Time was deemed to be fully vested, with any performance conditions deemed satisfied based on actual levels of achievement of applicable target levels as of November 19, 2025, and was cancelled and converted into the right to receive $105.00 in cash, without interest (the "Merger Consideration") in respect of each share of the Issuer's common stock, par value $0.01 per share ("Common Stock") subject to such PSU, less any applicable tax withholding. Row 2 · 2026-03-23 · Disposition to issuer · Disposed 1,397,738 · Balance 0 F3: At the Effective Time, on the terms and subject to the conditions set forth in the Merger Agreement, each share of Common Stock, issued and outstanding immediately prior to the Effective Time, with certain exceptions, was converted into the right to receive the Merger Consideration. |
| Common StockSEC Table I · non-derivative | IndirectHeld in 401(k) Plan | 0 |
Reported balance
After 2026-03-23 transaction · row 3
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 3 · 2026-03-23 · Disposition to issuer · Disposed 29,061 · Balance 0 F3: At the Effective Time, on the terms and subject to the conditions set forth in the Merger Agreement, each share of Common Stock, issued and outstanding immediately prior to the Effective Time, with certain exceptions, was converted into the right to receive the Merger Consideration. |
| Common StockSEC Table I · non-derivative | IndirectHeld in Grantor Retained Annuity Trust | 0 |
Reported balance
After 2026-03-23 transaction · row 4
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 4 · 2026-03-23 · Disposition to issuer · Disposed 46,538 · Balance 0 F3: At the Effective Time, on the terms and subject to the conditions set forth in the Merger Agreement, each share of Common Stock, issued and outstanding immediately prior to the Effective Time, with certain exceptions, was converted into the right to receive the Merger Consideration. |
| Common StockSEC Table I · non-derivative | IndirectHeld in Grantor Retained Annuity Trust | 0 |
Reported balance
After 2026-03-23 transaction · row 5
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 5 · 2026-03-23 · Disposition to issuer · Disposed 86,750 · Balance 0 F3: At the Effective Time, on the terms and subject to the conditions set forth in the Merger Agreement, each share of Common Stock, issued and outstanding immediately prior to the Effective Time, with certain exceptions, was converted into the right to receive the Merger Consideration. |
| Common StockSEC Table I · non-derivative | IndirectHeld in Grantor Retained Annuity Trust | 0 |
Reported balance
After 2026-03-23 transaction · row 6
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 6 · 2026-03-23 · Disposition to issuer · Disposed 117,427 · Balance 0 F3: At the Effective Time, on the terms and subject to the conditions set forth in the Merger Agreement, each share of Common Stock, issued and outstanding immediately prior to the Effective Time, with certain exceptions, was converted into the right to receive the Merger Consideration. |
| Stock Options (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $21.68 | Direct | 0 |
Reported balance
After 2026-03-23 transaction · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · 2026-03-23 · Disposition to issuer · Disposed 235,388 · Balance 0 F5: At the Effective Time, each option to purchase shares of Common Stock granted under an Issuer stock plan and outstanding and unexercised as of immediately prior to the Effective Time was cancelled and, in the case of any such option the per-share exercise price of which was less than the Merger Consideration, converted into the right to receive a cash payment equal to the number of shares of Common Stock for which such option was exercisable multiplied by the excess of the Merger Consideration over the per-share exercise price of such option, less any applicable tax withholding F4: These options became exercisable in full on February 23, 2021. |
| Stock Options (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $44.37 | Direct | 0 |
Reported balance
After 2026-03-23 transaction · row 8
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 8 · 2026-03-23 · Disposition to issuer · Disposed 66,047 · Balance 0 F5: At the Effective Time, each option to purchase shares of Common Stock granted under an Issuer stock plan and outstanding and unexercised as of immediately prior to the Effective Time was cancelled and, in the case of any such option the per-share exercise price of which was less than the Merger Consideration, converted into the right to receive a cash payment equal to the number of shares of Common Stock for which such option was exercisable multiplied by the excess of the Merger Consideration over the per-share exercise price of such option, less any applicable tax withholding F8: These options became exercisable on February 27, 2022. |
| Stock Options (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $92.62 | Direct | 0 |
Reported balance
After 2026-03-23 transaction · row 9
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 9 · 2026-03-23 · Disposition to issuer · Disposed 34,110 · Balance 0 F5: At the Effective Time, each option to purchase shares of Common Stock granted under an Issuer stock plan and outstanding and unexercised as of immediately prior to the Effective Time was cancelled and, in the case of any such option the per-share exercise price of which was less than the Merger Consideration, converted into the right to receive a cash payment equal to the number of shares of Common Stock for which such option was exercisable multiplied by the excess of the Merger Consideration over the per-share exercise price of such option, less any applicable tax withholding F9: These options became exercisable on February 26, 2023. |
| Stock Options (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $98.18 | Direct | 0 |
Reported balance
After 2026-03-23 transaction · row 10
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 10 · 2026-03-23 · Disposition to issuer · Disposed 100,916 · Balance 0 F5: At the Effective Time, each option to purchase shares of Common Stock granted under an Issuer stock plan and outstanding and unexercised as of immediately prior to the Effective Time was cancelled and, in the case of any such option the per-share exercise price of which was less than the Merger Consideration, converted into the right to receive a cash payment equal to the number of shares of Common Stock for which such option was exercisable multiplied by the excess of the Merger Consideration over the per-share exercise price of such option, less any applicable tax withholding F10: These options became exercisable on February 14, 2024. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2026-03-23 transaction · row 11
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 11 · 2026-03-23 · Disposition to issuer · Disposed 18,143 · Balance 0 F6: Each restricted stock unit ("RSU") represents a contingent right to receive one share of common stock. F7: At the Effective Time, each RSU granted under an Issuer stock plan before November 19, 2025 and outstanding as of immediately prior to the Effective Time was deemed to be fully vested and cancelled and converted into the right to receive the Merger Consideration in respect of each share of Common Stock subject to such RSU, less any applicable tax withholding. F15: These RSUs vest in four equal annual installments beginning on February 28, 2024. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2026-03-23 transaction · row 12
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 12 · 2026-03-23 · Disposition to issuer · Disposed 44,336 · Balance 0 F6: Each restricted stock unit ("RSU") represents a contingent right to receive one share of common stock. F7: At the Effective Time, each RSU granted under an Issuer stock plan before November 19, 2025 and outstanding as of immediately prior to the Effective Time was deemed to be fully vested and cancelled and converted into the right to receive the Merger Consideration in respect of each share of Common Stock subject to such RSU, less any applicable tax withholding. F11: These RSUs vest in four equal annual installments beginning on February 28, 2025. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2026-03-23 transaction · row 13
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 13 · 2026-03-23 · Disposition to issuer · Disposed 83,360 · Balance 0 F6: Each restricted stock unit ("RSU") represents a contingent right to receive one share of common stock. F7: At the Effective Time, each RSU granted under an Issuer stock plan before November 19, 2025 and outstanding as of immediately prior to the Effective Time was deemed to be fully vested and cancelled and converted into the right to receive the Merger Consideration in respect of each share of Common Stock subject to such RSU, less any applicable tax withholding. F12: These RSUs vest in four equal annual installments beginning on February 27, 2026. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2026-03-23 transaction · row 14
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 14 · 2026-03-23 · Disposition to issuer · Disposed 154,829 · Balance 0 F6: Each restricted stock unit ("RSU") represents a contingent right to receive one share of common stock. F14: At the Effective Time, each outstanding RSU as of immediately prior to the Effective Time that was granted on or after November 19, 2025 was assumed by Parent at the Effective Time as a Parent restricted stock unit on substantially the same terms and conditions as were applicable to the corresponding RSU (including with respect to double-trigger vesting protections), with the number of Parent common shares underlying such Parent restricted stock unit determined based on the Merger Consideration divided by the average closing price of a Parent common share for the 10 consecutive trading days ending on and including the trading day immediately preceding the Effective Time. F13: These RSUs vest in four equal annual installments beginning on February 25, 2027. |
Filing footnotes · ownership attribution and instrument terms
F1: On March 23, 2026, pursuant to the terms of that certain Agreement and Plan of Merger (the "Merger Agreement"), dated as of November 19, 2025, by and among Exact Sciences Corporation, a Delaware corporation (the "Issuer"), Abbott Laboratories, an Illinois corporation ("Parent"), and Badger Merger Sub I, Inc., a Delaware corporation and a direct, wholly owned subsidiary of Parent ("Merger Sub"), Merger Sub merged with and into the Issuer (the "Merger"), with the Issuer surviving the Merger as a direct, wholly owned subsidiary of Parent.
F2: At the effective time of the Merger (the "Effective Time"), each performance based restricted stock unit ("PSU") outstanding as of immediately prior to the Effective Time was deemed to be fully vested, with any performance conditions deemed satisfied based on actual levels of achievement of applicable target levels as of November 19, 2025, and was cancelled and converted into the right to receive $105.00 in cash, without interest (the "Merger Consideration") in respect of each share of the Issuer's common stock, par value $0.01 per share ("Common Stock") subject to such PSU, less any applicable tax withholding.
F3: At the Effective Time, on the terms and subject to the conditions set forth in the Merger Agreement, each share of Common Stock, issued and outstanding immediately prior to the Effective Time, with certain exceptions, was converted into the right to receive the Merger Consideration.
F4: These options became exercisable in full on February 23, 2021.
F5: At the Effective Time, each option to purchase shares of Common Stock granted under an Issuer stock plan and outstanding and unexercised as of immediately prior to the Effective Time was cancelled and, in the case of any such option the per-share exercise price of which was less than the Merger Consideration, converted into the right to receive a cash payment equal to the number of shares of Common Stock for which such option was exercisable multiplied by the excess of the Merger Consideration over the per-share exercise price of such option, less any applicable tax withholding
F6: Each restricted stock unit ("RSU") represents a contingent right to receive one share of common stock.
F7: At the Effective Time, each RSU granted under an Issuer stock plan before November 19, 2025 and outstanding as of immediately prior to the Effective Time was deemed to be fully vested and cancelled and converted into the right to receive the Merger Consideration in respect of each share of Common Stock subject to such RSU, less any applicable tax withholding.
F8: These options became exercisable on February 27, 2022.
F9: These options became exercisable on February 26, 2023.
F10: These options became exercisable on February 14, 2024.
F11: These RSUs vest in four equal annual installments beginning on February 28, 2025.
F12: These RSUs vest in four equal annual installments beginning on February 27, 2026.
F13: These RSUs vest in four equal annual installments beginning on February 25, 2027.
F14: At the Effective Time, each outstanding RSU as of immediately prior to the Effective Time that was granted on or after November 19, 2025 was assumed by Parent at the Effective Time as a Parent restricted stock unit on substantially the same terms and conditions as were applicable to the corresponding RSU (including with respect to double-trigger vesting protections), with the number of Parent common shares underlying such Parent restricted stock unit determined based on the Merger Consideration divided by the average closing price of a Parent common share for the 10 consecutive trading days ending on and including the trading day immediately preceding the Effective Time.
F15: These RSUs vest in four equal annual installments beginning on February 28, 2024.
Epizyme, Inc.
Report date August 12, 2022 · Filed August 16, 2022
Section 16 reporting ended · disclosed 2022-08-16. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common Stock, par value $0.0001SEC Table I · non-derivative | Direct | 0 |
Ending reported balance
After 2022-08-12 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2022-08-12 · Disposition to issuer · Disposed 53,324 · Balance 8,994 F1: Reflects disposition of shares of common stock of the Issuer ("Shares") in connection with that certain Agreement and Plan of Merger (the "Merger Agreement"), by and among the Issuer, Ipsen Pharma SAS and Hibernia Merger Sub, Inc. ("Merger Sub"), dated as of June 27, 2022, including the completion of a tender offer to purchase all outstanding Shares of the Issuer, at a price per Share of (i) $1.45 per Share (the "Cash Consideration"), plus (ii) one (1) contractual contingent value right per Share ("CVR"), which represents the right to receive one or more contingent payments upon the achievement of certain milestones, if any (collectively, the "Offer Price"), and the consummation of the merger (the "Merger") between the Issuer and Merger Sub on August 12, 2022. As of the effective time of the Merger (the "Effective Time"), each Share held by the Reporting Person was converted into the Offer Price. Row 2 · 2022-08-12 · Disposition to issuer · Disposed 8,994 · Balance 0 F2: Reflects disposition of restricted stock units ("RSUs") in accordance with the Merger Agreement, pursuant to which, effective immediately prior to the Effective Time, each unvested RSU held by the Reporting Person automatically vested in full and was canceled and converted into the right to receive (i) an amount of cash equal to the product of (A) the total number of Shares then underlying such RSU multiplied by (B) the Cash Consideration and (ii) one (1) CVR for each Share underlying such RSU, in each case, less applicable withholding. |
Filing footnotes · ownership attribution and instrument terms
F1: Reflects disposition of shares of common stock of the Issuer ("Shares") in connection with that certain Agreement and Plan of Merger (the "Merger Agreement"), by and among the Issuer, Ipsen Pharma SAS and Hibernia Merger Sub, Inc. ("Merger Sub"), dated as of June 27, 2022, including the completion of a tender offer to purchase all outstanding Shares of the Issuer, at a price per Share of (i) $1.45 per Share (the "Cash Consideration"), plus (ii) one (1) contractual contingent value right per Share ("CVR"), which represents the right to receive one or more contingent payments upon the achievement of certain milestones, if any (collectively, the "Offer Price"), and the consummation of the merger (the "Merger") between the Issuer and Merger Sub on August 12, 2022. As of the effective time of the Merger (the "Effective Time"), each Share held by the Reporting Person was converted into the Offer Price.
F2: Reflects disposition of restricted stock units ("RSUs") in accordance with the Merger Agreement, pursuant to which, effective immediately prior to the Effective Time, each unvested RSU held by the Reporting Person automatically vested in full and was canceled and converted into the right to receive (i) an amount of cash equal to the product of (A) the total number of Shares then underlying such RSU multiplied by (B) the Cash Consideration and (ii) one (1) CVR for each Share underlying such RSU, in each case, less applicable withholding.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| September 30, 2026 Filed Oct 3, 2026 00:10 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | GrantStock Equivalent Units · Derivative | 318 | $98.83 | $31,427.94 |
DisclosureSEC source: 0001104659-26-113286 · tm2626917-3_4seq1.xml · derivative · entry 1 Conroy Kevin T · CIK 0001306119 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 551 Underlying: Common Shares · 318 shares Expires not disclosed F1 · derivative.exercise_price: Director fees credited to a stock equivalent unit account under a grantor trust established by the director and paid, in cash, generally at age 65 or upon retirement from the board. The stock equivalent units earn the same return as if the fees were invested in Abbott stock. F1 · derivative.exercise_date: Director fees credited to a stock equivalent unit account under a grantor trust established by the director and paid, in cash, generally at age 65 or upon retirement from the board. The stock equivalent units earn the same return as if the fees were invested in Abbott stock. F1 · derivative.expiration_date: Director fees credited to a stock equivalent unit account under a grantor trust established by the director and paid, in cash, generally at age 65 or upon retirement from the board. The stock equivalent units earn the same return as if the fees were invested in Abbott stock. F2 · balance_after: Balance includes stock equivalent units acquired pursuant to a dividend reinvestment feature. Read SEC document |
| September 23, 2026 Filed Sep 25, 2026 21:21 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Tax withholdingCommon shares without par value | 52,507 | $103.99 | $5,460,202.93 |
DisclosureSEC source: 0001306119-26-000009 · form4-09252026_090910.xml · nonDerivative · entry 1 Conroy Kevin T · CIK 0001306119 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 81,230 Read SEC document |
| June 30, 2026 Filed Jul 1, 2026 21:28 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | GrantStock Equivalent Units · Derivative | 231 | $90.74 | $20,960.94 |
DisclosureSEC source: 0001306119-26-000006 · form4-07012026_090707.xml · derivative · entry 1 Conroy Kevin T · CIK 0001306119 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 231 Underlying: Common Shares · 231 shares Expires not disclosed F1 · derivative.exercise_price: Director fees credited to a stock equivalent unit account under a grantor trust established by the director and paid, in cash, generally at age 65 or upon retirement from the board. The stock equivalent units earn the same return as if the fees were invested in Abbott stock. F1 · derivative.exercise_date: Director fees credited to a stock equivalent unit account under a grantor trust established by the director and paid, in cash, generally at age 65 or upon retirement from the board. The stock equivalent units earn the same return as if the fees were invested in Abbott stock. F1 · derivative.expiration_date: Director fees credited to a stock equivalent unit account under a grantor trust established by the director and paid, in cash, generally at age 65 or upon retirement from the board. The stock equivalent units earn the same return as if the fees were invested in Abbott stock. Read SEC document |
| May 20, 2026 Filed May 22, 2026 23:08 UTC | ALIGN TECHNOLOGY INC ALGN · Entity 3488 | GrantRestricted Stock Units · Derivative | 1,836 | $0.00 | $0.00 |
DisclosureSEC source: 0001193125-26-237321 · ownership.xml · derivative · entry 3 Conroy Kevin T · CIK 0001306119 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,836 Underlying: Common Stock · 1,836 shares Expires not disclosed F2 · derivative.exercise_price: 100% of the RSUs granted on May 20, 2026 will become vested on the earlier of (i) May 20, 2027 or (ii) the date of the next annual meeting of stockholders. Shares will be delivered to the Reporting Person on such vesting date assuming the continued service of the Reporting Person on such vesting date. F2 · derivative.exercise_date: 100% of the RSUs granted on May 20, 2026 will become vested on the earlier of (i) May 20, 2027 or (ii) the date of the next annual meeting of stockholders. Shares will be delivered to the Reporting Person on such vesting date assuming the continued service of the Reporting Person on such vesting date. F2 · derivative.expiration_date: 100% of the RSUs granted on May 20, 2026 will become vested on the earlier of (i) May 20, 2027 or (ii) the date of the next annual meeting of stockholders. Shares will be delivered to the Reporting Person on such vesting date assuming the continued service of the Reporting Person on such vesting date. Read SEC document |
| May 20, 2026 Filed May 22, 2026 23:08 UTC | ALIGN TECHNOLOGY INC ALGN · Entity 3488 | Exercise / conversionRestricted Stock Units · Derivative | 1,745 | $0.00 | $0.00 |
DisclosureSEC source: 0001193125-26-237321 · ownership.xml · derivative · entry 2 Conroy Kevin T · CIK 0001306119 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 1,745 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: 100% of the restricted stock units ("RSUs") granted on May 21, 2025 vested on May 20, 2026 and shares were delivered to the Reporting Person. F1 · derivative.exercise_date: 100% of the restricted stock units ("RSUs") granted on May 21, 2025 vested on May 20, 2026 and shares were delivered to the Reporting Person. F1 · derivative.expiration_date: 100% of the restricted stock units ("RSUs") granted on May 21, 2025 vested on May 20, 2026 and shares were delivered to the Reporting Person. Read SEC document |
| May 20, 2026 Filed May 22, 2026 23:08 UTC | ALIGN TECHNOLOGY INC ALGN · Entity 3488 | Exercise / conversionCommon Stock | 1,745 | $0.00 | $0.00 |
DisclosureSEC source: 0001193125-26-237321 · ownership.xml · nonDerivative · entry 1 Conroy Kevin T · CIK 0001306119 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,553 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| April 24, 2026 Filed Apr 29, 2026 00:07 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | GrantCommon shares without par value | 2,286 | $0.00 | $0.00 |
DisclosureSEC source: 0001306119-26-000004 · form4-04292026_120423.xml · nonDerivative · entry 1 Conroy Kevin T · CIK 0001306119 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 133,737 F1 · shares: Restricted stock unit award granted under the Abbott Laboratories 2026 Incentive Stock Program (the "Program"). The award will be paid, on a one-to-one basis, in Abbott common shares on the earlier of the date of the director's separation from service, death, or the occurrence of a change in control (as defined by the Program). Read SEC document |
| March 23, 2026 Filed Mar 23, 2026 09:20 UTC | EXACT SCIENCES CORP EXAS · Entity 56619 | Disposition to issuerRestricted Stock Units · Derivative | 154,829 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001193125-26-118755 · ownership.xml · derivative · entry 14 Conroy Kevin T · CIK 0001306119 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 154,829 shares Expires not disclosed F6 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of common stock. F14 · price: At the Effective Time, each outstanding RSU as of immediately prior to the Effective Time that was granted on or after November 19, 2025 was assumed by Parent at the Effective Time as a Parent restricted stock unit on substantially the same terms and conditions as were applicable to the corresponding RSU (including with respect to double-trigger vesting protections), with the number of Parent common shares underlying such Parent restricted stock unit determined based on the Merger Consideration divided by the average closing price of a Parent common share for the 10 consecutive trading days ending on and including the trading day immediately preceding the Effective Time. F13 · derivative.exercise_date: These RSUs vest in four equal annual installments beginning on February 25, 2027. F13 · derivative.expiration_date: These RSUs vest in four equal annual installments beginning on February 25, 2027. Read SEC document |
| March 23, 2026 Filed Mar 23, 2026 09:20 UTC | EXACT SCIENCES CORP EXAS · Entity 56619 | Disposition to issuerRestricted Stock Units · Derivative | 83,360 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001193125-26-118755 · ownership.xml · derivative · entry 13 Conroy Kevin T · CIK 0001306119 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 83,360 shares Expires not disclosed F6 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of common stock. F7 · price: At the Effective Time, each RSU granted under an Issuer stock plan before November 19, 2025 and outstanding as of immediately prior to the Effective Time was deemed to be fully vested and cancelled and converted into the right to receive the Merger Consideration in respect of each share of Common Stock subject to such RSU, less any applicable tax withholding. F12 · derivative.exercise_date: These RSUs vest in four equal annual installments beginning on February 27, 2026. F12 · derivative.expiration_date: These RSUs vest in four equal annual installments beginning on February 27, 2026. Read SEC document |
| March 23, 2026 Filed Mar 23, 2026 09:20 UTC | EXACT SCIENCES CORP EXAS · Entity 56619 | Disposition to issuerRestricted Stock Units · Derivative | 44,336 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001193125-26-118755 · ownership.xml · derivative · entry 12 Conroy Kevin T · CIK 0001306119 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 44,336 shares Expires not disclosed F6 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of common stock. F7 · price: At the Effective Time, each RSU granted under an Issuer stock plan before November 19, 2025 and outstanding as of immediately prior to the Effective Time was deemed to be fully vested and cancelled and converted into the right to receive the Merger Consideration in respect of each share of Common Stock subject to such RSU, less any applicable tax withholding. F11 · derivative.exercise_date: These RSUs vest in four equal annual installments beginning on February 28, 2025. F11 · derivative.expiration_date: These RSUs vest in four equal annual installments beginning on February 28, 2025. Read SEC document |
| March 23, 2026 Filed Mar 23, 2026 09:20 UTC | EXACT SCIENCES CORP EXAS · Entity 56619 | Disposition to issuerRestricted Stock Units · Derivative | 18,143 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001193125-26-118755 · ownership.xml · derivative · entry 11 Conroy Kevin T · CIK 0001306119 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 18,143 shares Expires not disclosed F6 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of common stock. F7 · price: At the Effective Time, each RSU granted under an Issuer stock plan before November 19, 2025 and outstanding as of immediately prior to the Effective Time was deemed to be fully vested and cancelled and converted into the right to receive the Merger Consideration in respect of each share of Common Stock subject to such RSU, less any applicable tax withholding. F15 · derivative.exercise_date: These RSUs vest in four equal annual installments beginning on February 28, 2024. F15 · derivative.expiration_date: These RSUs vest in four equal annual installments beginning on February 28, 2024. Read SEC document |
| March 23, 2026 Filed Mar 23, 2026 09:20 UTC | EXACT SCIENCES CORP EXAS · Entity 56619 | Disposition to issuerStock Options (Right to Buy) · Derivative | 100,916 | Not disclosed Strike: $98.18 | Not disclosed |
DisclosureSEC source: 0001193125-26-118755 · ownership.xml · derivative · entry 10 Conroy Kevin T · CIK 0001306119 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 100,916 shares Expires not disclosed F5 · price: At the Effective Time, each option to purchase shares of Common Stock granted under an Issuer stock plan and outstanding and unexercised as of immediately prior to the Effective Time was cancelled and, in the case of any such option the per-share exercise price of which was less than the Merger Consideration, converted into the right to receive a cash payment equal to the number of shares of Common Stock for which such option was exercisable multiplied by the excess of the Merger Consideration over the per-share exercise price of such option, less any applicable tax withholding F10 · derivative.exercise_date: These options became exercisable on February 14, 2024. F10 · derivative.expiration_date: These options became exercisable on February 14, 2024. Read SEC document |
| March 23, 2026 Filed Mar 23, 2026 09:20 UTC | EXACT SCIENCES CORP EXAS · Entity 56619 | Disposition to issuerStock Options (Right to Buy) · Derivative | 34,110 | Not disclosed Strike: $92.62 | Not disclosed |
DisclosureSEC source: 0001193125-26-118755 · ownership.xml · derivative · entry 9 Conroy Kevin T · CIK 0001306119 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 34,110 shares Expires not disclosed F5 · price: At the Effective Time, each option to purchase shares of Common Stock granted under an Issuer stock plan and outstanding and unexercised as of immediately prior to the Effective Time was cancelled and, in the case of any such option the per-share exercise price of which was less than the Merger Consideration, converted into the right to receive a cash payment equal to the number of shares of Common Stock for which such option was exercisable multiplied by the excess of the Merger Consideration over the per-share exercise price of such option, less any applicable tax withholding F9 · derivative.exercise_date: These options became exercisable on February 26, 2023. F9 · derivative.expiration_date: These options became exercisable on February 26, 2023. Read SEC document |
| March 23, 2026 Filed Mar 23, 2026 09:20 UTC | EXACT SCIENCES CORP EXAS · Entity 56619 | Disposition to issuerStock Options (Right to Buy) · Derivative | 66,047 | Not disclosed Strike: $44.37 | Not disclosed |
DisclosureSEC source: 0001193125-26-118755 · ownership.xml · derivative · entry 8 Conroy Kevin T · CIK 0001306119 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 66,047 shares Expires not disclosed F5 · price: At the Effective Time, each option to purchase shares of Common Stock granted under an Issuer stock plan and outstanding and unexercised as of immediately prior to the Effective Time was cancelled and, in the case of any such option the per-share exercise price of which was less than the Merger Consideration, converted into the right to receive a cash payment equal to the number of shares of Common Stock for which such option was exercisable multiplied by the excess of the Merger Consideration over the per-share exercise price of such option, less any applicable tax withholding F8 · derivative.exercise_date: These options became exercisable on February 27, 2022. F8 · derivative.expiration_date: These options became exercisable on February 27, 2022. Read SEC document |
| March 23, 2026 Filed Mar 23, 2026 09:20 UTC | EXACT SCIENCES CORP EXAS · Entity 56619 | Disposition to issuerStock Options (Right to Buy) · Derivative | 235,388 | Not disclosed Strike: $21.68 | Not disclosed |
DisclosureSEC source: 0001193125-26-118755 · ownership.xml · derivative · entry 7 Conroy Kevin T · CIK 0001306119 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 235,388 shares Expires not disclosed F5 · price: At the Effective Time, each option to purchase shares of Common Stock granted under an Issuer stock plan and outstanding and unexercised as of immediately prior to the Effective Time was cancelled and, in the case of any such option the per-share exercise price of which was less than the Merger Consideration, converted into the right to receive a cash payment equal to the number of shares of Common Stock for which such option was exercisable multiplied by the excess of the Merger Consideration over the per-share exercise price of such option, less any applicable tax withholding F4 · derivative.exercise_date: These options became exercisable in full on February 23, 2021. F4 · derivative.expiration_date: These options became exercisable in full on February 23, 2021. Read SEC document |
| March 23, 2026 Filed Mar 23, 2026 09:20 UTC | EXACT SCIENCES CORP EXAS · Entity 56619 | Disposition to issuerCommon Stock | 117,427 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001193125-26-118755 · ownership.xml · nonDerivative · entry 6 Conroy Kevin T · CIK 0001306119 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Indirect · Held in Grantor Retained Annuity Trust Disclosed balance after: 0 F3 · price: At the Effective Time, on the terms and subject to the conditions set forth in the Merger Agreement, each share of Common Stock, issued and outstanding immediately prior to the Effective Time, with certain exceptions, was converted into the right to receive the Merger Consideration. Read SEC document |
| March 23, 2026 Filed Mar 23, 2026 09:20 UTC | EXACT SCIENCES CORP EXAS · Entity 56619 | Disposition to issuerCommon Stock | 86,750 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001193125-26-118755 · ownership.xml · nonDerivative · entry 5 Conroy Kevin T · CIK 0001306119 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Indirect · Held in Grantor Retained Annuity Trust Disclosed balance after: 0 F3 · price: At the Effective Time, on the terms and subject to the conditions set forth in the Merger Agreement, each share of Common Stock, issued and outstanding immediately prior to the Effective Time, with certain exceptions, was converted into the right to receive the Merger Consideration. Read SEC document |
| March 23, 2026 Filed Mar 23, 2026 09:20 UTC | EXACT SCIENCES CORP EXAS · Entity 56619 | Disposition to issuerCommon Stock | 46,538 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001193125-26-118755 · ownership.xml · nonDerivative · entry 4 Conroy Kevin T · CIK 0001306119 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Indirect · Held in Grantor Retained Annuity Trust Disclosed balance after: 0 F3 · price: At the Effective Time, on the terms and subject to the conditions set forth in the Merger Agreement, each share of Common Stock, issued and outstanding immediately prior to the Effective Time, with certain exceptions, was converted into the right to receive the Merger Consideration. Read SEC document |
| March 23, 2026 Filed Mar 23, 2026 09:20 UTC | EXACT SCIENCES CORP EXAS · Entity 56619 | Disposition to issuerCommon Stock | 29,061 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001193125-26-118755 · ownership.xml · nonDerivative · entry 3 Conroy Kevin T · CIK 0001306119 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Indirect · Held in 401(k) Plan Disclosed balance after: 0 F3 · price: At the Effective Time, on the terms and subject to the conditions set forth in the Merger Agreement, each share of Common Stock, issued and outstanding immediately prior to the Effective Time, with certain exceptions, was converted into the right to receive the Merger Consideration. Read SEC document |
| March 23, 2026 Filed Mar 23, 2026 09:20 UTC | EXACT SCIENCES CORP EXAS · Entity 56619 | Disposition to issuerCommon Stock | 1,397,738 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001193125-26-118755 · ownership.xml · nonDerivative · entry 2 Conroy Kevin T · CIK 0001306119 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 F3 · price: At the Effective Time, on the terms and subject to the conditions set forth in the Merger Agreement, each share of Common Stock, issued and outstanding immediately prior to the Effective Time, with certain exceptions, was converted into the right to receive the Merger Consideration. Read SEC document |
| March 23, 2026 Filed Mar 23, 2026 09:20 UTC | EXACT SCIENCES CORP EXAS · Entity 56619 | GrantCommon Stock | 119,312 | $0.00 | $0.00 |
DisclosureSEC source: 0001193125-26-118755 · ownership.xml · nonDerivative · entry 1 Conroy Kevin T · CIK 0001306119 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,397,738 F1 · shares: On March 23, 2026, pursuant to the terms of that certain Agreement and Plan of Merger (the "Merger Agreement"), dated as of November 19, 2025, by and among Exact Sciences Corporation, a Delaware corporation (the "Issuer"), Abbott Laboratories, an Illinois corporation ("Parent"), and Badger Merger Sub I, Inc., a Delaware corporation and a direct, wholly owned subsidiary of Parent ("Merger Sub"), Merger Sub merged with and into the Issuer (the "Merger"), with the Issuer surviving the Merger as a direct, wholly owned subsidiary of Parent. F2 · shares: At the effective time of the Merger (the "Effective Time"), each performance based restricted stock unit ("PSU") outstanding as of immediately prior to the Effective Time was deemed to be fully vested, with any performance conditions deemed satisfied based on actual levels of achievement of applicable target levels as of November 19, 2025, and was cancelled and converted into the right to receive $105.00 in cash, without interest (the "Merger Consideration") in respect of each share of the Issuer's common stock, par value $0.01 per share ("Common Stock") subject to such PSU, less any applicable tax withholding. Read SEC document |
| February 27, 2026 Filed Mar 3, 2026 19:16 UTC | EXACT SCIENCES CORP EXAS · Entity 56619 | Exercise / conversionRestricted Stock Units · Derivative | 27,786 | $0.00 | $0.00 |
DisclosureSEC source: 0001193125-26-089303 · ownership.xml · derivative · entry 13 Conroy Kevin T · CIK 0001306119 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 83,360 Underlying: Common Stock · 27,768 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of common stock. F7 · derivative.exercise_date: Represents a restricted stock unit award granted on February 24, 2025 that partially vested on February 27, 2026. The restricted stock units vest in four equal annual installments on the last trading day of February. F7 · derivative.expiration_date: Represents a restricted stock unit award granted on February 24, 2025 that partially vested on February 27, 2026. The restricted stock units vest in four equal annual installments on the last trading day of February. Read SEC document |
| February 27, 2026 Filed Mar 3, 2026 19:16 UTC | EXACT SCIENCES CORP EXAS · Entity 56619 | Exercise / conversionRestricted Stock Units · Derivative | 22,168 | $0.00 | $0.00 |
DisclosureSEC source: 0001193125-26-089303 · ownership.xml · derivative · entry 12 Conroy Kevin T · CIK 0001306119 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 44,336 Underlying: Common Stock · 22,168 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of common stock. F6 · derivative.exercise_date: Represents a restricted stock unit award granted on February 26, 2024 that partially vested on February 27, 2026. The restricted stock units vest in four equal annual installments on the last trading day of February. F6 · derivative.expiration_date: Represents a restricted stock unit award granted on February 26, 2024 that partially vested on February 27, 2026. The restricted stock units vest in four equal annual installments on the last trading day of February. Read SEC document |
| February 27, 2026 Filed Mar 3, 2026 19:16 UTC | EXACT SCIENCES CORP EXAS · Entity 56619 | Exercise / conversionRestricted Stock Units · Derivative | 18,143 | $0.00 | $0.00 |
DisclosureSEC source: 0001193125-26-089303 · ownership.xml · derivative · entry 11 Conroy Kevin T · CIK 0001306119 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 18,143 Underlying: Common Stock · 18,143 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of common stock. F5 · derivative.exercise_date: Represents a restricted stock unit award granted on February 24, 2023 that partially vested on February 27, 2026. The restricted stock units vest in four equal annual installments on the last trading day of February. F5 · derivative.expiration_date: Represents a restricted stock unit award granted on February 24, 2023 that partially vested on February 27, 2026. The restricted stock units vest in four equal annual installments on the last trading day of February. Read SEC document |
| February 27, 2026 Filed Mar 3, 2026 19:16 UTC | EXACT SCIENCES CORP EXAS · Entity 56619 | Tax withholdingCommon Stock | 13,060 | $103.25 | $1,348,445.00 |
DisclosureSEC source: 0001193125-26-089303 · ownership.xml · nonDerivative · entry 6 Conroy Kevin T · CIK 0001306119 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,278,045 F2 · shares: Represents shares of Common Stock retained by Exact Sciences Corporation for tax withholding purposes in connection with the net-settlement on the issuance of shares of Common Stock in respect to the vesting of certain restricted stock units. F3 · balance_after: In addition to the shares of Common Stock reported on this Form 4, which total 1,557,821 shares, Mr. Conroy also holds, in the aggregate, an additional 737,129 vested and unvested options to purchase shares of Common Stock and restricted stock units, with each restricted stock unit representing a contingent right to receive one share of Common Stock. Read SEC document |
| February 27, 2026 Filed Mar 3, 2026 19:16 UTC | EXACT SCIENCES CORP EXAS · Entity 56619 | Exercise / conversionCommon Stock | 27,786 | $0.00 | $0.00 |
DisclosureSEC source: 0001193125-26-089303 · ownership.xml · nonDerivative · entry 5 Conroy Kevin T · CIK 0001306119 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,291,105 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: Represents shares of common stock received upon vesting of a restricted stock unit award. Read SEC document |
| February 27, 2026 Filed Mar 3, 2026 19:16 UTC | EXACT SCIENCES CORP EXAS · Entity 56619 | Tax withholdingCommon Stock | 10,419 | $103.25 | $1,075,761.75 |
DisclosureSEC source: 0001193125-26-089303 · ownership.xml · nonDerivative · entry 4 Conroy Kevin T · CIK 0001306119 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,263,319 F2 · shares: Represents shares of Common Stock retained by Exact Sciences Corporation for tax withholding purposes in connection with the net-settlement on the issuance of shares of Common Stock in respect to the vesting of certain restricted stock units. Read SEC document |
| February 27, 2026 Filed Mar 3, 2026 19:16 UTC | EXACT SCIENCES CORP EXAS · Entity 56619 | Exercise / conversionCommon Stock | 22,168 | $0.00 | $0.00 |
DisclosureSEC source: 0001193125-26-089303 · ownership.xml · nonDerivative · entry 3 Conroy Kevin T · CIK 0001306119 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,273,738 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: Represents shares of common stock received upon vesting of a restricted stock unit award. Read SEC document |
| February 27, 2026 Filed Mar 3, 2026 19:16 UTC | EXACT SCIENCES CORP EXAS · Entity 56619 | Tax withholdingCommon Stock | 8,528 | $103.25 | $880,516.00 |
DisclosureSEC source: 0001193125-26-089303 · ownership.xml · nonDerivative · entry 2 Conroy Kevin T · CIK 0001306119 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,251,570 F2 · shares: Represents shares of Common Stock retained by Exact Sciences Corporation for tax withholding purposes in connection with the net-settlement on the issuance of shares of Common Stock in respect to the vesting of certain restricted stock units. Read SEC document |
| February 27, 2026 Filed Mar 3, 2026 19:16 UTC | EXACT SCIENCES CORP EXAS · Entity 56619 | Exercise / conversionCommon Stock | 18,143 | $0.00 | $0.00 |
DisclosureSEC source: 0001193125-26-089303 · ownership.xml · nonDerivative · entry 1 Conroy Kevin T · CIK 0001306119 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,260,098 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: Represents shares of common stock received upon vesting of a restricted stock unit award. Read SEC document |
| February 25, 2026 Filed Feb 27, 2026 16:30 UTC | EXACT SCIENCES CORP EXAS · Entity 56619 | GrantRestricted Stock Units · Derivative | 154,829 | $0.00 | $0.00 |
DisclosureSEC source: 0001193125-26-082828 · ownership.xml · derivative · entry 7 Conroy Kevin T · CIK 0001306119 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 154,829 Underlying: Common Stock · 154,829 shares Expires not disclosed F4 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of common stock. F5 · derivative.exercise_date: These restricted stock units vest in four equal annual installments beginning on February 25, 2027. F5 · derivative.expiration_date: These restricted stock units vest in four equal annual installments beginning on February 25, 2027. Read SEC document |
| February 25, 2026 Filed Feb 27, 2026 16:30 UTC | EXACT SCIENCES CORP EXAS · Entity 56619 | Tax withholdingCommon Stock | 6,196 | $103.45 | $640,976.20 |
DisclosureSEC source: 0001193125-26-082828 · ownership.xml · nonDerivative · entry 2 Conroy Kevin T · CIK 0001306119 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,241,955 F2 · shares: Represents shares of Common Stock retained by the Issuer for tax withholding purposes in connection with the net-settlement on the issuance of shares of Common Stock in respect to the vesting of certain restricted stock units. F3 · balance_after: In addition to the shares of Common Stock reported on this Form 4, which total 1,521,721 shares, Mr. Conroy also holds, in the aggregate, an additional 805,226 vested and unvested options to purchase shares of Common Stock and restricted stock units, with each restricted stock unit representing a contingent right to receive one share of Common Stock. Read SEC document |
| February 25, 2026 Filed Feb 27, 2026 16:30 UTC | EXACT SCIENCES CORP EXAS · Entity 56619 | GrantCommon Stock | 13,181 | $0.00 | $0.00 |
DisclosureSEC source: 0001193125-26-082828 · ownership.xml · nonDerivative · entry 1 Conroy Kevin T · CIK 0001306119 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,248,151 F1 · shares: Represents shares of common stock received upon vesting of a restricted stock unit award. Read SEC document |
| December 23, 2025 Filed Dec 30, 2025 16:30 UTC | EXACT SCIENCES CORP EXAS · Entity 56619 | Tax withholdingCommon Stock | 155,417 | $101.82 | $15,824,558.94 |
DisclosureSEC source: 0001193125-25-337153 · ownership.xml · nonDerivative · entry 6 Conroy Kevin T · CIK 0001306119 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,234,970 F2 · shares: Represents shares of Common Stock retained by the Issuer for tax withholding purposes in connection with the net-settlement on the issuance of shares of Common Stock in respect to the vesting of certain performance based restricted stock units. F5 · balance_after: In addition to the shares of Common Stock reported on this Form 4, which total 1,514,491 shares, Mr. Conroy also holds, in the aggregate, an additional 663,578 vested and unvested options to purchase shares of Common Stock and restricted stock units, with each restricted stock unit representing a contingent right to receive one share of Common Stock Read SEC document |
| December 23, 2025 Filed Dec 30, 2025 16:30 UTC | EXACT SCIENCES CORP EXAS · Entity 56619 | GrantCommon Stock | 330,674 | $0.00 | $0.00 |
DisclosureSEC source: 0001193125-25-337153 · ownership.xml · nonDerivative · entry 5 Conroy Kevin T · CIK 0001306119 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 155,417 F4 · shares: Represents performance-based restricted share units granted to the reporting person on February 24, 2025 and that were scheduled to vest or be forfeited based on the attainment of performance-based vesting conditions during the performance period ending on December 31, 2027. The vesting of the portion reflected herein was accelerated in connection with the Section 280G Mitigation. Read SEC document |
| December 23, 2025 Filed Dec 30, 2025 16:30 UTC | EXACT SCIENCES CORP EXAS · Entity 56619 | Tax withholdingCommon Stock | 65,014 | $101.82 | $6,619,725.48 |
DisclosureSEC source: 0001193125-25-337153 · ownership.xml · nonDerivative · entry 4 Conroy Kevin T · CIK 0001306119 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,059,713 F2 · shares: Represents shares of Common Stock retained by the Issuer for tax withholding purposes in connection with the net-settlement on the issuance of shares of Common Stock in respect to the vesting of certain performance based restricted stock units. Read SEC document |
| December 23, 2025 Filed Dec 30, 2025 16:30 UTC | EXACT SCIENCES CORP EXAS · Entity 56619 | GrantCommon Stock | 138,326 | $0.00 | $0.00 |
DisclosureSEC source: 0001193125-25-337153 · ownership.xml · nonDerivative · entry 3 Conroy Kevin T · CIK 0001306119 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,124,727 F3 · shares: Represents performance-based restricted share units granted to the reporting person on February 26, 2024 and that were scheduled to vest or be forfeited based on the attainment of performance-based vesting conditions during the performance period ending on December 31, 2026. The vesting of the portion reflected herein was accelerated in connection with the Section 280G Mitigation. Read SEC document |
| December 23, 2025 Filed Dec 30, 2025 16:30 UTC | EXACT SCIENCES CORP EXAS · Entity 56619 | Tax withholdingCommon Stock | 115,118 | $101.82 | $11,721,314.76 |
DisclosureSEC source: 0001193125-25-337153 · ownership.xml · nonDerivative · entry 2 Conroy Kevin T · CIK 0001306119 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 986,401 F2 · shares: Represents shares of Common Stock retained by the Issuer for tax withholding purposes in connection with the net-settlement on the issuance of shares of Common Stock in respect to the vesting of certain performance based restricted stock units. Read SEC document |
| December 23, 2025 Filed Dec 30, 2025 16:30 UTC | EXACT SCIENCES CORP EXAS · Entity 56619 | GrantCommon Stock | 244,931 | $0.00 | $0.00 |
DisclosureSEC source: 0001193125-25-337153 · ownership.xml · nonDerivative · entry 1 Conroy Kevin T · CIK 0001306119 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,101,519 F1 · shares: Represents performance-based restricted share units granted to the reporting person on February 24, 2023 and that were scheduled to vest or be forfeited based on the attainment of performance-based vesting conditions during the performance period ending on December 31, 2025. The vesting of the portion reflected herein was accelerated in order to mitigate the potential impact of Sections 280G and 4999 of the Internal Revenue Code of 1986, as amended, on the Issuer and certain of its employees in connection with the pending transactions contemplated by the Agreement and Plan of Merger, dated November 19, 2025, by and among the Issuer, Abbott Laboratories, and Badger Merger Sub I, Inc. (the "Section 280G Mitigation"). Read SEC document |
| May 21, 2025 Filed May 22, 2025 21:49 UTC | ALIGN TECHNOLOGY INC ALGN · Entity 3488 | GrantRestricted Stock Units · Derivative | 1,745 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001415889-25-014232 · form4-05222025_090543.xml · derivative · entry 3 Conroy Kevin T · CIK 0001306119 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,745 Underlying: Common Stock · 1,745 shares Expires not disclosed F1 · derivative.exercise_price: Represents par value of ALGN common stock. F3 · derivative.exercise_date: 100% of the RSUs granted on May 21, 2025 will become vested on the earlier of (i) May 21, 2026 or (ii) the date of the next annual meeting of stockholders. Shares will be delivered to the Reporting Person on such vesting date assuming the continued service of the Reporting Person on such vesting date. F3 · derivative.expiration_date: 100% of the RSUs granted on May 21, 2025 will become vested on the earlier of (i) May 21, 2026 or (ii) the date of the next annual meeting of stockholders. Shares will be delivered to the Reporting Person on such vesting date assuming the continued service of the Reporting Person on such vesting date. Read SEC document |
| May 21, 2025 Filed May 22, 2025 21:49 UTC | ALIGN TECHNOLOGY INC ALGN · Entity 3488 | Exercise / conversionRestricted Stock Units · Derivative | 1,148 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001415889-25-014232 · form4-05222025_090543.xml · derivative · entry 2 Conroy Kevin T · CIK 0001306119 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 1,148 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Represents par value of ALGN common stock. F2 · derivative.exercise_date: 100% of the restricted stock units ("RSUs") granted on May 22, 2024 vested on May 21, 2025 and shares were delivered to the Reporting Person. F2 · derivative.expiration_date: 100% of the restricted stock units ("RSUs") granted on May 22, 2024 vested on May 21, 2025 and shares were delivered to the Reporting Person. Read SEC document |
| May 21, 2025 Filed May 22, 2025 21:49 UTC | ALIGN TECHNOLOGY INC ALGN · Entity 3488 | Exercise / conversionCommon Stock | 1,148 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-25-014232 · form4-05222025_090543.xml · nonDerivative · entry 1 Conroy Kevin T · CIK 0001306119 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,808 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 07, 2025 Filed Mar 10, 2025 17:00 UTC | EXACT SCIENCES CORP EXAS · Entity 56619 | Exercise / conversionStock Options (Right to Buy) · Derivative | 66,723 | $0.00 Strike: $22.38 | $0.00 |
DisclosureSEC source: 0000950170-25-036484 · ownership.xml · derivative · entry 10 Conroy Kevin T · CIK 0001306119 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 66,723 shares Expires 2025-03-09 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Mr. Conroy was awarded 71,000 stock options on March 9, 2015. 66,723 of these stock options were not exercised during the 10-year term of the award. Under the terms of the options, they were automatically exercised on the business day preceding the expiration date of the options, and 48,929 shares were withheld from Mr. Conroy to pay the exercise price and taxes due upon exercise of the options. As a result, Mr. Conroy increased his holdings of Exact Sciences shares by 17,794 shares or approximately 1.6%. Read SEC document |
| March 07, 2025 Filed Mar 10, 2025 17:00 UTC | EXACT SCIENCES CORP EXAS · Entity 56619 | Tax withholdingCommon Stock | 48,929 | $47.06 | $2,302,598.74 |
DisclosureSEC source: 0000950170-25-036484 · ownership.xml · nonDerivative · entry 2 Conroy Kevin T · CIK 0001306119 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,154,340 F1 · kind: Mr. Conroy was awarded 71,000 stock options on March 9, 2015. 66,723 of these stock options were not exercised during the 10-year term of the award. Under the terms of the options, they were automatically exercised on the business day preceding the expiration date of the options, and 48,929 shares were withheld from Mr. Conroy to pay the exercise price and taxes due upon exercise of the options. As a result, Mr. Conroy increased his holdings of Exact Sciences shares by 17,794 shares or approximately 1.6%. F2 · balance_after: In addition to the shares of Common Stock reported on this Form 4, which total 1,494,973 shares, Mr. Conroy also holds, in the aggregate, an additional 663,578 vested and unvested options to purchase shares of Common Stock and restricted stock units, with each restricted stock unit representing a contingent right to receive one share of Common Stock. Read SEC document |
| March 07, 2025 Filed Mar 10, 2025 17:00 UTC | EXACT SCIENCES CORP EXAS · Entity 56619 | Exercise / conversionCommon Stock | 66,723 | $22.38 | $1,493,260.74 |
DisclosureSEC source: 0000950170-25-036484 · ownership.xml · nonDerivative · entry 1 Conroy Kevin T · CIK 0001306119 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,203,269 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Mr. Conroy was awarded 71,000 stock options on March 9, 2015. 66,723 of these stock options were not exercised during the 10-year term of the award. Under the terms of the options, they were automatically exercised on the business day preceding the expiration date of the options, and 48,929 shares were withheld from Mr. Conroy to pay the exercise price and taxes due upon exercise of the options. As a result, Mr. Conroy increased his holdings of Exact Sciences shares by 17,794 shares or approximately 1.6%. Read SEC document |
| February 28, 2025 Filed Mar 4, 2025 16:47 UTC | EXACT SCIENCES CORP EXAS · Entity 56619 | Exercise / conversionRestricted Stock Units · Derivative | 22,167 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-25-032293 · ownership.xml · derivative · entry 13 Conroy Kevin T · CIK 0001306119 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 66,504 Underlying: Common Stock · 22,167 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of common stock. F6 · derivative.exercise_date: Represents a restricted stock unit award granted on February 26, 2024 that partially vested on February 28, 2025. The restricted stock units vest in four equal annual installments on the last trading day of February. F6 · derivative.expiration_date: Represents a restricted stock unit award granted on February 26, 2024 that partially vested on February 28, 2025. The restricted stock units vest in four equal annual installments on the last trading day of February. Read SEC document |
| February 28, 2025 Filed Mar 4, 2025 16:47 UTC | EXACT SCIENCES CORP EXAS · Entity 56619 | Exercise / conversionRestricted Stock Units · Derivative | 18,143 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-25-032293 · ownership.xml · derivative · entry 12 Conroy Kevin T · CIK 0001306119 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 36,286 Underlying: Common Stock · 18,143 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of common stock. F5 · derivative.exercise_date: Represents a restricted stock unit award granted on February 24, 2023 that partially vested on February 28, 2025. The restricted stock units vest in four equal annual installments on the last trading day of February. F5 · derivative.expiration_date: Represents a restricted stock unit award granted on February 24, 2023 that partially vested on February 28, 2025. The restricted stock units vest in four equal annual installments on the last trading day of February. Read SEC document |
| February 28, 2025 Filed Mar 4, 2025 16:47 UTC | EXACT SCIENCES CORP EXAS · Entity 56619 | Tax withholdingCommon Stock | 10,419 | $47.82 | $498,236.58 |
DisclosureSEC source: 0000950170-25-032293 · ownership.xml · nonDerivative · entry 4 Conroy Kevin T · CIK 0001306119 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,136,546 F2 · shares: Represents shares of Common Stock retained by Exact Sciences Corporation for tax withholding purposes in connection with the net-settlement on the issuance of shares of Common Stock in respect to the vesting of certain restricted stock units. F3 · balance_after: In addition to the shares of Common Stock reported on this Form 4, which total 1,477,179 shares, Mr. Conroy also holds, in the aggregate, an additional 730,301 vested and unvested options to purchase shares of Common Stock and restricted stock units, with each restricted stock unit representing a contingent right to receive one share of Common Stock. Read SEC document |
| February 28, 2025 Filed Mar 4, 2025 16:47 UTC | EXACT SCIENCES CORP EXAS · Entity 56619 | Exercise / conversionCommon Stock | 22,167 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-25-032293 · ownership.xml · nonDerivative · entry 3 Conroy Kevin T · CIK 0001306119 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,146,965 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: Represents shares of common stock received upon vesting of a restricted stock unit award. Read SEC document |
| February 28, 2025 Filed Mar 4, 2025 16:47 UTC | EXACT SCIENCES CORP EXAS · Entity 56619 | Tax withholdingCommon Stock | 8,528 | $47.82 | $407,808.96 |
DisclosureSEC source: 0000950170-25-032293 · ownership.xml · nonDerivative · entry 2 Conroy Kevin T · CIK 0001306119 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,124,798 F2 · shares: Represents shares of Common Stock retained by Exact Sciences Corporation for tax withholding purposes in connection with the net-settlement on the issuance of shares of Common Stock in respect to the vesting of certain restricted stock units. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.